Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Vigil Neuroscience, Inc. - Common Stock
(NQ:
VIGL
)
4.300
+0.100 (+2.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vigil Neuroscience, Inc. - Common Stock
< Previous
1
2
Next >
Vigil Neuroscience to Present at Stifel 2023 CNS Days
March 22, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 21, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting
March 02, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team
December 15, 2022
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP
December 14, 2022
First-ever interventional trial for patients with ALSP, a rare and rapidly progressing neurological disease with significant unmet medical need
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022
November 28, 2022
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience to Present at Upcoming Investor Conferences
November 07, 2022
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP
November 02, 2022
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP
November 01, 2022
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne Bruhn, Ph.D.
July 28, 2022
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.